Effects of Vitamin D Supplementation During Pregnancy on Preterm Birth Risk and Maternal-Neonatal Outcomes: A Systematic Review and Meta-Analysis of 38 Randomized Controlled Trials
Lulu Zuo , Jiaojiao Wang , Xinyan Xie , Mei Peng , Jieyu He , Qiong Lu , Zhaokai Zhou , Qiyue Zheng
BIO Integration ›› 2026, Vol. 7 ›› Issue (1) : 32
Background and objective: Preterm birth complications are among leading causes of mortality in neonates and children under 5 years of age worldwide. The association between prenatal vitamin D supplementation and risk of preterm birth is controversial based on randomized controlled trials (RCTs). We aimed to determine the effect of vitamin D supplementation during pregnancy on preterm birth and maternal and neonatal secondary outcomes, and to ascertain whether the effects of vitamin D supplementation on preterm birth differed by baseline 25(OH)D status, supplementation dose, and timing of initiation.
Data sources: PubMed, Web of Science, Medline, Cochrane Library, and Embase were searched from inception to April 2023 with no language restrictions.
Study selection: RCTs comparing vitamin D supplementation with placebo, no treatment, or standard low-dose vitamin D (≤ 600 IU/day) in pregnant women were included. The primary outcome was preterm birth (<37 weeks’ gestation) and secondary outcomes included maternal adverse events and neonatal anthropometric indicators.
Results: Thirty-eight RCTs involving 17,392 pregnant women were included. Nineteen RCTs involving 7959 pregnant women reported preterm birth. Vitamin D supplementation was associated with a borderline increase in preterm birth risk in the primary analysis (RR, 1.13; 95% CI, 1.01–1.26; P = 0.04; I2 = 0%) but this association was modest and largely driven by one large RCT among women living with HIV. An increased preterm birth signal was noted among participants with a baseline 25(OH)D ≥ 30 nmol/L (OR, 1.25; 95% CI, 1.05–1.48) in exploratory subgroup analyses presented as ORs and this signal was entirely derived from the same HIV trial. No significant subgroup associations were detected in the < 30 nmol/L subgroup or by supplementation dose or initiation timing. No significant effects were noted for maternal or neonatal secondary outcomes.
Limitations: The main study limitations included incomplete reporting of preterm births across trials, reliance on the risk signal on a single population-specific risk signal, dichotomization of baseline 25(OH)D status, and lack of individual participant data for refined subgroup analyses.
Conclusions: Current evidence does not support universal vitamin D supplementation to prevent preterm birth. A possible increased risk of preterm birth among participants with a baseline 25(OH)D ≥ 30 nmol/L should be interpreted cautiously because this finding was driven by a single trial in HIV-positive pregnant women and should not be generalized to healthy pregnant women. Further large-scale RCTs and individual participant data meta-analyses are warranted to clarify whether baseline vitamin D status modifies effects of vitamin D supplementation.
Maternal outcomes / neonatal outcomes / pregnancy / preterm birth / randomized controlled trials / vitamin D
| [1] |
WHO: recommended definitions, terminology and format for statistical tables related to the perinatal period and use of a new certificate for cause of perinatal deaths. Modifications recommended by FIGO as amended October 14, 1976. Acta Obstet Gynecol Scand 1977; 56(3): 247-53. [PMID: 560099] |
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
/
| 〈 |
|
〉 |